A phase II, randomised, double-blind, placebo-controlled, parallel group, multicentre study investigating efficacy and safety of Sepranolone (UC1010) in patients with PMDD

Trial Profile

A phase II, randomised, double-blind, placebo-controlled, parallel group, multicentre study investigating efficacy and safety of Sepranolone (UC1010) in patients with PMDD

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Sepranolone (Primary)
  • Indications Premenstrual dysphoric disorder
  • Focus Therapeutic Use
  • Sponsors Asarina Pharma
  • Most Recent Events

    • 24 Nov 2017 Status changed from planning to recruiting.
    • 15 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top